US2014227274A1PendingUtilityA1

Prevention and Treatment of Amyloidogenic Disease

68
Assignee: SCHENK DALE BPriority: Dec 2, 1997Filed: Sep 3, 2013Published: Aug 14, 2014
Est. expiryDec 2, 2017(expired)· nominal 20-yr term from priority
Inventors:Dale B. Schenk
A61P 43/00A61P 37/00A61P 25/28A61P 25/00A61K 31/00A61K 2039/505A61K 2039/55555C07K 16/18A61K 38/1709A61K 9/2031A61K 47/646A61K 2039/55505A61K 2039/53A61K 9/0019A61K 2039/55566A61K 2039/6037C07K 2317/24A61K 9/4866A61K 2039/55572C07K 2319/00A61K 2039/55577A61K 31/739A61K 9/7023A61K 9/2009A61K 38/193C07K 14/4711C07K 2317/567A61K 9/2054A61K 39/0007A61K 2039/605A61K 39/00
68
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is Aβ peptide, active fragments thereof or an antibody thereto.

Claims

exact text as granted — not AI-modified
1 . A method of preventing or treating a disease characterized by amyloid deposit in a patient, comprising administering an effective dosage of an antibody that specifically binds to the amyloid deposit or a component thereof to the patient. 
     
     
         2 - 37 . (canceled) 
     
     
         38 . A method of preventing or treating Alzheimer's disease, comprising administering an effective dosage of a polypeptide comprising an active fragment of Aβ that induces an immune response to Aβ in the patient. 
     
     
         39 - 52 . (canceled) 
     
     
         53 . A pharmaceutical composition comprising an active fragment of Aβ effective to induce a response to Aβ in a patient and an adjuvant. 
     
     
         54 - 163 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.